中山为什么上大厕会出血中山便血 不疼不痒,中山哪里治疗肛瘘手术比较好,中山便血块的原因有哪些,中山华都肛泰医院在线,中山青少年脱肛医院,中山那家外痔医院最好,中山关于屁股大便出血

KATHMANDU, Aug. 3 (Xinhua) -- Two glaciers in Nepal that shrank at an accelerated rate in the past 10 years compared to preceding decades will inevitably disappear from rising temperatures as no fresh snow supply is expected for them, a new research by Japan's Nagoya University says.According to Wednesday's Republica daily, the masses of the Yala glacier of Langtang Himal in central Nepal and the AX010 glacier of Shorong Himal in the Khumbu region shrank annually by 0. 8 meters and 0.81 meters respectively in the 2000s, which was a significant acceleration from the 0.68 and 0.72 meters of shrinkage per year between 1970 and 1990, said findings of the research published in a journal of the National Academy of Sciences of the United States on Tuesday."If the trend since the 1990s continues for the Yala and AX010 glaciers, the disappearance of these glaciers is inevitable because they are about to lose their accumulation areas, thus, no snow supply is expected for these glaciers," says the research conducted by Koji Fujita and Takayuki Nuimura.The researchers also found that while the shrinking of glaciers has accelerated in humid environments, the opposite is true for those in arid environments. The shrinking of Rikha Samba glacier located in the Kaligandaki Hidden Valley slowed from 0.57 meters per year between 1970 and 1990 to 0.48 meters per year in the 2000s."A comparison of the mass balance results and annual precipitation reveals that glacier wastage has been accelerated in humid environments but suppressed in an arid environment," the research says.Apart from environment, altitude also appears to play a role in the lifespan of glaciers, the researchers say. Rikha Samba is located at an altitude of 5,700 meters where loss of mass from melting could be compensated to some extent by collection of snowfall.The Yala glacier and AX010, on the other hand, are located at lower altitudes of 5,400 meters and 5,200 meters respectively.

WASHINGTON, June 8 (Xinhua) -- Hundreds of small genetic variations are associated with autism spectrum disorders, including an area of DNA that may be a key to understanding why humans are social animals, according to a multi-site collaborative study led by researchers at Yale University.To be published Thursday in the journal Neuron, the study reinforces the theory that autism, a disorder that develops in early childhood involving impairments in social interaction, language deficits and distinctive behaviors, is not caused by one or two major genetic defects, but by many small variations, each associated with a small percentage of cases.The study looked at more than 1,000 families in which there was a single child with an autism spectrum disorder, an unaffected sibling and unaffected parents. The team compared individuals with autism to their siblings to determine what types of genetic changes distinguished the affected child from the unaffected child.One of the most intriguing of these findings points to the same small section of the genome that causes Williams syndrome -- a developmental disorder marked by high sociability and an unusual aptitude for music.In autism, there is an increase in the chromosomal material, an extra copy of this region, and in Williams syndrome, there's a loss of that same material," said lead author Matthew State. "What makes this observation particularly interesting is that Williams syndrome is known for a personality type that is highly empathetic, social, and sensitive to the emotional state of others. Individuals with autism often have difficulties in the opposite direction. This suggests that there is an important key in that region to understanding the nature of the social brain."State and his team also found about 30 other regions in the genome that are very likely contributing to autism and are focused on about six of those regions that showed the strongest evidence."We're now moving on to a second phase of the study looking at an additional 1,600 families and should be able to identify multiple new regions that are strongly implicated in autism," he said.

WELLINGTON, May 31 (Xinhua) -- New Zealand agricultural produce regulators cleared an Auckland-based firm that exported infant formula to China of food safety concerns, just hours after confirming they had launched an investigation.The clarification came the same day Kiaora New Zealand International, marketers of Heitiki infant formula, apologized for using a Maori name and icon on its product packaging.The Ministry of Agriculture and Forestry (MAF) issued a statement Tuesday to say Kiaora New Zealand had been cleared of food safety and export regulations concerns, but an investigation into the labeling and marketing of Heitiki would continue.The MAF issued a statement earlier Tuesday confirming reports it was investigating the product's safety, but MAF compliance and enforcement director Geoff Allen said in a later statement the investigation had been underway for about 10 days."The investigation was triggered by our internal surveillance. The investigation was primarily on whether there was a food safety issue, and I'm pleased to report that no food safety issues were identified," said Allen.Nothing "untoward" was identified in the origin and export destination of Heitiki-branded products, which were manufactured in New Zealand according to legal requirements, said Allen."The investigation has now turned to the labeling and marketing of the product. This aspect is ongoing, and seeks to identify anything in the labeling or marketing that is inaccurate or misleading.

TOKYO, Sept. 23 (Xinhua) -- Japan's H-2A rocket carrying a new information gathering satellite was launched at the Tanegashima Space Center in Kagoshima Prefecture on Friday, local media reported.Japan has already introduced three information-gathering satellites in the wake of a missile launch by Democratic People's Republic of Korea, and the latest one will replace the No. 2 satellite which has passed its use-by date, Kydo News said.Japan's H-2A rocket lifts off from the launchiung pad at the Tanegashima space centre in Kagoshima prefecture, Japan's southern island of Kyushu on September 23, 2011. Japan launched a new spy satellite into orbit September 23, officials saidThe development cost of the fourth satellite has reached 35.9 billion yen and its launch expenses have come to 10.4 billion yen, according to the government.The Japan Aerospace Exploration Agency and Mitsubishi Heavy Industries Ltd. were forced to put off the launch three times during the past four weeks due to the approach of a powerful typhoon and discovery of a system glitch. The rocket was initially scheduled to be sent into orbit on Aug. 28.

WELLINGTON, June 7 (Xinhua) -- Scientists in New Zealand have developed a new drug to fight previously untreatable hypoxic cancer tumors, which form in areas of the body starved of oxygen.The researchers at the Auckland University have entered an agreement for the clinical development of CEN-209, which was developed over 10 years of research, said a statement from the university Tuesday.CEN-209 was designed to enhance the effectiveness of radiotherapy and chemotherapy in solid hypoxic tumors, which were resistant to standard cancer therapies, said the statement. In lung cancer patients for example, about half of tumors had hypoxic regions.The new drug worked by damaging the DNA of hypoxic cancer cells, while leaving normal, healthy tissues alone.CEN-209 was designed and created by researchers at the university's Auckland Cancer Society Research Centre (ACSRC), using computer models of drug transport within tumors to accurately predict the anti-tumor activity of the drugs."Our computer models of drug transport developed in-house allowed the synthetic chemists to test their design theories and considerably shortened the discovery process," said Associate Professor Michael Hay, who led the ACSRC research chemists."CEN-209 improves markedly on previous agents in this class in terms of its ability to penetrate tumors, and this is reflected by its improved activity in the laboratory, when combined with long or short courses of radiotherapy," said researcher Professor Bill Wilson.Under the agreement between the university's Auckland UniServices Ltd. and California-based Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc., Centella will have exclusive rights to CEN-209, which it will develop and trial with Cancer Research UK.The work on CEN-209 is the culmination of a program initiated with funding from the U.S. National Cancer Institute, and more recently from the Maurice Wilkins Centre for Biodiscovery. Ongoing preclinical research on CEN-209 and a backup compound was funded by grants from the Auckland Medical Research Foundation, Genesis Oncology Trust and Health Research Council of New Zealand, said the statement.